GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » Common Stock

Ocugen (MEX:OCGN) Common Stock : MXN60.79 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ocugen Common Stock?

Ocugen's quarterly common stock increased from Jun. 2024 (MXN47.19 Mil) to Sep. 2024 (MXN57.18 Mil) and increased from Sep. 2024 (MXN57.18 Mil) to Dec. 2024 (MXN60.79 Mil).

Ocugen's annual common stock increased from Dec. 2022 (MXN43.22 Mil) to Dec. 2023 (MXN43.57 Mil) and increased from Dec. 2023 (MXN43.57 Mil) to Dec. 2024 (MXN60.79 Mil).


Ocugen Common Stock Historical Data

The historical data trend for Ocugen's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Common Stock Chart

Ocugen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.62 40.93 43.22 43.57 60.79

Ocugen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.57 42.74 47.19 57.18 60.79

Ocugen Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Ocugen Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").